Growing Prevalence Of Different Types Of Cancers To Uplift The Growth Of The Dual Specificity Protein Kinase TTK Market

 

The growing prevalence of different types of cancers around the globe is one of the prime factors driving the growth of the dual specificity protein kinase TTK market. Cancers such as breast cancer, solid tumor, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and prostate cancer are highly prevalent across developed countries. According to Cancer Research UK, it is expected that around 17 million new cases of cancer will be registered across the globe in 2018. Moreover, as per the U.S. National Library of Medicine and National Institutes of Health, pancreatic ductal adenocarcinoma is one of the most lethal cancers worldwide with the highest incidence rates found in North America and in Western Europe while lower rates in Asian Africa, with the incidence rates of 7.2 and 2.8 per 100,000 populations, respectively in 2017.

Furthermore, a growing number of pipeline molecules of dual-specificity protein kinase TTK as a targeted drug for different types of cancer is projected to augment the growth of the dual specificity protein kinase TTK market.

North America is expected to dominate the global dual-specificity protein kinase TTK market and this is accredited to the growing investment in the research and development activities in the oncology segment in the region. According to the National Cancer Institute, estimated national expenditures for cancer care in the United States in 2018 were $150.8 billion. In future years, costs are likely to increase as the population ages and more people have cancer. Costs are also likely to increase as new, and often more expensive, treatments are adopted as standards of care.

Dual Specificity Protein Kinase has been found to be very efficient in stimulating the growth of cells, and in the process, it helps in reducing the damage done to tissues by free radicals. It also helps in removing harmful toxins, thus preventing diseases like diabetes and cancer. Moreover,  it has the ability to stimulate the production of the growth hormone. This will help stimulate the muscles, which in turn, increase the energy supply to the body and at the same time, will contribute to the weight loss process of an individual. This new kind of protein kinase has been found effective in increasing the amount of growth hormone released by the pituitary gland. This, in turn, will also help in decreasing the weight of an individual

Major players operating in the dual specificity protein kinase TTK market include Bayer AG, Boston Pharmaceuticals, Les Laboratoires Servier SAS, Nerviano Medical Sciences Srl, Netherlands Translational Research Center BV, and Pfizer Inc.